CHF doctors need better survival prediction tools. Neutrophil-to-lymphocyte ratio (NLR) shows promise as inflammation marker. Researchers, in a study published in the Cardiology Research and Practice, analyzed NHANES data from 1999-2018. They studied 566 CHF patients. Data split 7:3 into training and validation sets. Multivariate Cox regression found key factors. NLR, age, and gender increased death risk. Hemoglobin and platelets protected survival. They built nomogram using these five factors.
Nomogram Shows Strong Prediction Power
Training set AUCs reached 0.822 at 3 years. Five-year AUC was 0.82. Ten-year AUC hit 0.803. Validation set performed well too. AUCs were 0.726, 0.769, and 0.775 at 3, 5, and 10 years. Calibration curves confirmed accuracy. Decision curve analysis proved clinical value.
Risk Groups Show Clear Survival Gap
High NLR patients had worse prognosis. Low nomogram scores predicted better survival. Kaplan-Meier curves separated risk groups clearly. Log-rank test gave P<0.001 significance. High-risk patients died much sooner.
Easy Blood Test Changes CHF Care
Cardiologists gain bedside tool using routine CBC. NLR calculation takes seconds. Age, gender, hemoglobin, and platelets add precision. Nomogram outperforms single markers. Risk stratification guides therapy intensity. High-risk patients need ICD evaluation. Low-risk patients avoid overtreatment. Annual recalculation tracks treatment response.
Integrate Into Routine CHF Management
Electronic medical records can automate NLR-nomogram calculation. Risk scores trigger multidisciplinary review. Heart failure clinics use scores for transplant listing. Palliative care engages highest risk quartiles. Simple bloodwork transforms precision prognostication across CHF spectrum.